QQQ   427.07 (-0.93%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   427.07 (-0.93%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   427.07 (-0.93%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
QQQ   427.07 (-0.93%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)

Fusion Pharmaceuticals (FUSN) Stock Price, News & Analysis

$21.26
0.00 (0.00%)
(As of 01:33 PM ET)
Today's Range
$21.22
$21.32
50-Day Range
$9.34
$21.43
52-Week Range
$2.31
$21.55
Volume
218,512 shs
Average Volume
2.08 million shs
Market Capitalization
$1.80 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.25

Fusion Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Hold
2.07 Rating Score
Upside/​Downside
4.6% Downside
$20.25 Price Target
Short Interest
Healthy
6.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.24mentions of Fusion Pharmaceuticals in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.46) to ($1.69) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.76 out of 5 stars

Medical Sector

856th out of 930 stocks

Biological Products, Except Diagnostic Industry

147th out of 155 stocks

FUSN stock logo

About Fusion Pharmaceuticals Stock (NASDAQ:FUSN)

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.

FUSN Stock Price History

FUSN Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Unveiling 11 Analyst Insights On Fusion Pharmaceuticals
Super Micro, XPeng, AstraZeneca: Trending tickers
See More Headlines
Receive FUSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2024
Today
4/17/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FUSN
Fax
N/A
Employees
101
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.25
High Stock Price Target
$24.00
Low Stock Price Target
$15.00
Potential Upside/Downside
-4.8%
Consensus Rating
Hold
Rating Score (0-4)
2.07
Research Coverage
14 Analysts

Profitability

Net Income
$-94,900,000.00
Net Margins
-4,136.55%
Pretax Margin
-4,550.77%

Debt

Sales & Book Value

Annual Sales
$2.07 million
Book Value
$3.07 per share

Miscellaneous

Free Float
78,129,000
Market Cap
$1.80 billion
Optionable
Optionable
Beta
-0.72
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. John F. Valliant Ph.D. (Age 53)
    Founder, CEO & Director
    Comp: $864.72k
  • Dr. Eric Burak Ph.D. (Age 59)
    Chief Technology Officer
    Comp: $638.04k
  • Mr. Mohit Rawat (Age 44)
    President & Chief Business Officer
  • Dr. Christopher Paul Leamon Ph.D. (Age 58)
    Chief Scientific Officer
  • Ms. Amanda Cray
    Senior Director of Investor Relations & Corporate Communications
  • Ms. Maria D. Stahl (Age 53)
    Chief Legal Officer
  • Mr. Eric S. Hoffman Ph.D. (Age 54)
    Senior Vice President of Business Development
  • Dr. Cara Ferreira Ph.D.
    Chief of Staff
  • Dr. Joanne Schindler
    Executive Vice President of Medical Director & Clinical Development
  • Dr. Dmitri Bobilev M.D. (Age 57)
    Chief Medical Officer

FUSN Stock Analysis - Frequently Asked Questions

Should I buy or sell Fusion Pharmaceuticals stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fusion Pharmaceuticals in the last year. There are currently 13 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" FUSN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FUSN, but not buy additional shares or sell existing shares.
View FUSN analyst ratings
or view top-rated stocks.

What is Fusion Pharmaceuticals' stock price target for 2024?

14 Wall Street research analysts have issued 1 year target prices for Fusion Pharmaceuticals' stock. Their FUSN share price targets range from $15.00 to $24.00. On average, they expect the company's share price to reach $20.25 in the next year. This suggests that the stock has a possible downside of 4.6%.
View analysts price targets for FUSN
or view top-rated stocks among Wall Street analysts.

How have FUSN shares performed in 2024?

Fusion Pharmaceuticals' stock was trading at $9.61 at the beginning of the year. Since then, FUSN stock has increased by 120.8% and is now trading at $21.22.
View the best growth stocks for 2024 here
.

When is Fusion Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our FUSN earnings forecast
.

How were Fusion Pharmaceuticals' earnings last quarter?

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) posted its quarterly earnings data on Wednesday, March, 20th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.05. Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative trailing twelve-month return on equity of 46.59%.

What ETFs hold Fusion Pharmaceuticals' stock?

ETFs with the largest weight of Fusion Pharmaceuticals (NASDAQ:FUSN) stock in their portfolio include ProShares Merger ETF (MRGR) and IQ Merger Arbitrage ETF (MNA).Fidelity Disruptive Medicine ETF (FMED).

What other stocks do shareholders of Fusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fusion Pharmaceuticals investors own include Overstock.com (OSTK), U.S. Xpress Enterprises (USX), Camping World (CWH), DocuSign (DOCU), Pfizer (PFE), Pure Storage (PSTG), CrowdStrike (CRWD), Livongo Health (LVGO), NVIDIA (NVDA) and OPKO Health (OPK).

When did Fusion Pharmaceuticals IPO?

Fusion Pharmaceuticals (FUSN) raised $126 million in an initial public offering on Friday, June 26th 2020. The company issued 8,400,000 shares at $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Fusion Pharmaceuticals?

Shares of FUSN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FUSN) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners